SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
SystImmune是(shi)一種家發生臨床藥學(xue)檢驗(yan)階段性的最前沿海洋(yang)生物(wu)(wu)藥業有(you)限(xian)(xian)新有(you)限(xian)(xian)公(gong)(gong)司(si)新有(you)限(xian)(xian)公(gong)(gong)司(si)，精(jing)益求精(jing)于發掘應用在胃癌診療(liao)的創新雙特(te)情(qing)人、多特(te)情(qing)人免(mian)疫免(mian)疫抗(kang)體(ti)及(ji)免(mian)疫免(mian)疫抗(kang)體(ti)中成藥偶聯物(wu)(wu)（ADCs）。新有(you)限(xian)(xian)公(gong)(gong)司(si)本文(wen)組(zu)閣調(diao)任(ren)(ren)Jonathan Cheng教(jiao)授(shou)為(wei)SystImmune現任(ren)(ren)總裁(cai)大人中醫學(xue)官。在注入SystImmune以前，Cheng教(jiao)授(shou)在百時美(mei)施(shi)貴寶兼(jian)任(ren)(ren)層級副經理裁(cai)兼(jian)良(liang)性肺部(bu)腫瘤(liu)進展組(zu)長，承擔治理抗(kang)良(liang)性肺部(bu)腫瘤(liu)供水管道(dao)的臨床藥學(xue)檢驗(yan)晚期發掘。確(que)認某次調(diao)任(ren)(ren)，Cheng 教(jiao)授(shou)繼任(ren)(ren)了Martin Olivo 教(jiao)授(shou)，由是(shi)為(wei)找(zhao)到對(dui)外部(bu)進展就(jiu)會已(yi)逃離SystImmune。
“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Ｅxecutive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”
SystImmune首席總裁程序(xu)執(zhi)行官Jie D'Elia醫(yi)(yi)生研究(jiu)生表現(xian)：“我很興(xing)奮并(bing)熱烈歡迎Cheng醫(yi)(yi)生研究(jiu)生加入(ru)到人們(men)都的(de)(de)上級領(ling)(ling)導銷售組織。他在(zai)全球最大腫癌(ai)用量制作這個領(ling)(ling)域的(de)(de)專業技術沉淀出(chu)的(de)(de)和對領(ling)(ling)域風(feng)險管控的(de)(de)深入(ru)表達(da)，將(jiang)提速(su)SystImmune的(de)(de)輸油管線進度，并(bing)舉一步驟積極推動人們(men)都對糖尿(niao)病患者(zhe)治療方法的(de)(de)變化。我謹體現(xian)SystImmune銷售組織，向(xiang)Martin Olivo醫(yi)(yi)生研究(jiu)生對公的(de)(de)司的(de)(de)堅守表現(xian)深切(qie)的(de)(de)感謝。人們(men)都祝賀他在(zai)將(jiang)來任何東西(xi)順利進行。”
Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Ｅxecutive leadership team.”
SystImmune監事長朱義博士研究生后說：“Cheng博士研究生后在肉瘤藥設計方向擁用豐富的的專業課程只是和優秀的營業收入，他的引入讓SystImmune管理者公司比較做強。”
Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.
Cheng博(bo)(bo)(bo)土(tu)(tu)的(de)(de)事業(ye)(ye)之路橫跨醫藥(yao)化(hua)工(gong)業(ye)(ye)職(zhi)業(ye)(ye)和(he)(he)科研(yan)界，在(zai)助推惡(e)性(xing)惡(e)性(xing)淋巴癌癥(zheng)冶療角(jiao)度(du)時常展露(lu)了極客的(de)(de)帶領(ling)工(gong)作能力(li)和(he)(he)熱情似火。在(zai)他(ta)的(de)(de)帶領(ling)下，BMS定制開發并香港(gang)出現(xian)(xian)了好幾種(zhong)關(guan)鍵(jian)性(xing)類藥(yao)，收錄Nivolumab、Ipilimumab、Relatlimab和(he)(he)Repotrectinib。他(ta)的(de)(de)策略遠見卓(zhuo)識，增加了該新公(gong)司組織結構(gou)產品設備線同時配合地埋管(guan)的(de)(de)寡(gua)頭壟(long)斷力(li)。在(zai)成為BMS先(xian)前(qian)，Cheng博(bo)(bo)(bo)土(tu)(tu)為默沙東惡(e)性(xing)淋巴癌癥(zheng)監床學(xue)(xue)習(xi)副(fu)總(zong)經理裁，并帶領(ling)銷售團(tuan)隊有Pembrolizumab和(he)(he)Lenvatinib在(zai)多(duo)惡(e)性(xing)淋巴癌癥(zheng)認(ren)知癥(zheng)的(de)(de)香港(gang)出現(xian)(xian)新批(pi)。在(zai)進去醫藥(yao)化(hua)工(gong)業(ye)(ye)職(zhi)業(ye)(ye)先(xian)前(qian)，Cheng博(bo)(bo)(bo)土(tu)(tu)在(zai) Fox Chase 惡(e)性(xing)惡(e)性(xing)淋巴癌癥(zheng)中心的(de)(de)有成功失敗的(de)(de)科研(yan)之路。他(ta)對于惡(e)性(xing)淋巴癌癥(zheng)栽(zai)培基質微植物學(xue)(xue)的(de)(de)總(zong)裁學(xue)(xue)習(xi)員，采取了輝煌性(xing)的(de)(de)學(xue)(xue)習(xi)，并進行150 多(duo)張原狀畫稿和(he)(he)小結。Cheng博(bo)(bo)(bo)土(tu)(tu)提(ti)升馬凱超大專碩士(shi)學(xue)(xue)士(shi)學(xue)(xue)位和(he)(he)明尼(ni)蘇(su)達(da)大專醫學(xue)(xue)界博(bo)(bo)(bo)土(tu)(tu)學(xue)(xue)士(shi)學(xue)(xue)位。
For further information, please contact: info@systimmune.com
如需很多(duo)訊息，請認識:info@systimmune.com
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
有(you)關于SystImmune
SystImmune都(dou)(dou)是家最靠(kao)近華盛頓州雷德蒙德的(de)(de)趨(qu)(qu)于穩定(ding)臨(lin)床藥理(li)(li)檢(jian)驗(yan)(yan)上上時(shi)段(duan)的(de)(de)生(sheng)態(tai)學生(sheng)物制(zhi)(zhi)藥業(ye)渠(qu)道(dao)(dao)(dao)。該渠(qu)道(dao)(dao)(dao)潛(qian)心于合理(li)(li)利用其成(cheng)長(chang)期的(de)(de)腫瘤(liu)制(zhi)(zhi)療(liao)(liao)用量設(she)(she)計(ji)渠(qu)道(dao)(dao)(dao)，設(she)(she)計(ji)自主創(chuang)新的(de)(de)肺(fei)癌(ai)診療(liao)(liao)步驟(zou)，屬于雙(shuang)炎癥因(yin)子(zi)聊天(tian)、多炎癥因(yin)子(zi)聊天(tian)抗體陽性(xing)陽性(xing)及抗體陽性(xing)陽性(xing)腫瘤(liu)制(zhi)(zhi)療(liao)(liao)用量偶聯(lian)物（ADCs）。SystImmune在實物瘤(liu)和靜脈血病教育鄰域的(de)(de)多種臨(lin)床藥理(li)(li)檢(jian)驗(yan)(yan)上上校(xiao)正時(shi)段(duan)均都(dou)(dou)有的(de)(de)的(de)(de)管(guan)道(dao)(dao)(dao)和水(shui)平存儲。除(chu)過目前在實現(xian)的(de)(de)臨(lin)床藥理(li)(li)檢(jian)驗(yan)(yan)上上校(xiao)正外(wai)，渠(qu)道(dao)(dao)(dao)還都(dou)(dou)有的(de)(de)強有力(li)的(de)(de)臨(lin)床藥理(li)(li)檢(jian)驗(yan)(yan)上上前的(de)(de)管(guan)道(dao)(dao)(dao)，屬于趨(qu)(qu)于穩定(ding)發展(zhan)時(shi)段(duan)或IND時(shi)段(duan)的(de)(de)未知(zhi)肺(fei)癌(ai)診療(liao)(liao)腫瘤(liu)制(zhi)(zhi)療(liao)(liao)用量，象征著渠(qu)道(dao)(dao)(dao)在生(sheng)態(tai)學生(sheng)物制(zhi)(zhi)藥業(ye)設(she)(she)計(ji)教育鄰域的(de)(de)當先水(shui)平。
